1-(1H-吲唑-5-基)乙酮 | 1001906-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-(1H-吲唑-5-基)乙酮
• 英文名称: 1-(1H-indazol-5-yl)ethan-1-one
• 英文别名: 1-(1H-indazole-5-yl)-ethanone；1-(1H-indazol-5-yl)ethanone
• CAS: 1001906-63-3
• 化学式: C₉H₈N₂O
• mdl: MFCD11869763
• 分子量: 160.175
• InChiKey: WYLOAPVBIBQLJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(1H-吲唑-5-基)乙酮 在 4-二甲氨基吡啶 、 pyridinium hydrobromide perbromide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 4-(1H-indazol-5-yl)-N-phenyl-1,3-thiazol-2-amine
  参考文献：
  名称：

  Scaffold oriented synthesis. Part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions

  摘要：

  We report the synthesis and biological evaluation of 5-substituted indazoles as kinase inhibitors. The compounds were synthesized in a parallel synthesis fashion from readily available starting materials employing heterocycle forming and multicomponent reactions and were evaluated against a panel of kinase assays. Potent inhibitors were identified for Gsk3 beta, Rock2, and Egfr. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.001
• 作为产物：
  描述：

  吲唑-5-甲酸盐酸盐 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 1-(1H-吲唑-5-基)乙酮
  参考文献：
  名称：

  Scaffold oriented synthesis. Part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions

  摘要：

  We report the synthesis and biological evaluation of 5-substituted indazoles as kinase inhibitors. The compounds were synthesized in a parallel synthesis fashion from readily available starting materials employing heterocycle forming and multicomponent reactions and were evaluated against a panel of kinase assays. Potent inhibitors were identified for Gsk3 beta, Rock2, and Egfr. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.001

文献信息

• [EN] AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME<br/>[FR] DÉRIVÉS AMIDES UTILISÉS EN TANT QUE LIGANDS DE CANAUX IONIQUES ET COMPOSITIONS PHARMACEUTIQUES AINSI QUE LEURS MÉTHODES D'UTILISATION
  申请人：RENOVIS INS

  公开号：WO2009089057A1

  公开（公告）日：2009-07-16

  Compounds are disclosed that have a formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  抱歉，我无法提供直接翻译结果。但是，我可以帮您理解这段文字的含义。这段文字描述了一些化合物，其化学式如下所示：(I)。这些化合物可以制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤等。
• DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120058986A1

  公开（公告）日：2012-03-08

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下式（I）表示： 其中Q和Z在此处定义。
• OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120077797A1

  公开（公告）日：2012-03-29

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (Ia) and Formula (Ib) as follows: wherein Y, Z, and n are defined herein; and wherein Y b and Z b are as defined herein.

  本文披露了用于治疗各种疾病、综合症、状况和障碍，包括疼痛的化合物、组合物和方法。这些化合物及其对映体、二对映体和药学上可接受的盐由以下的化学式(Ia)和化学式(Ib)表示：其中Y、Z和n在此定义；以及其中Yband Zbare如此定义。
• [EN] HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES UTILISÉS EN TANT QU'INHIBITEURS DE VANINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2020114949A1

  公开（公告）日：2020-06-11

  The present invention encompasses compounds of the formula I, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

  本发明涵盖了式I的化合物，适用于治疗与Vanin相关的疾病，以及制备这些化合物的方法、含有这些化合物的药物制剂，以及它们的使用方法。
• SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS
  申请人：Kawashima Tadashi

  公开号：US20090253740A1

  公开（公告）日：2009-10-08

  This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一个公式(I)的化合物，以及它们用于治疗由VR1受体过度激活引起的疾病状态，如哺乳动物中的疼痛等。本发明还提供了包含上述化合物的药物组合物。